title: Obesity-resistant S5B rats showed greater cocaine conditioned place preference than the obesity-prone OM rats.
abstract: BACKGROUND
  Dopamine (DA) and the DA D2 receptor (D2R) are involved in the rewarding and conditioned responses to food and drug rewards. Osborne-Mendel (OM) rats are genetically prone and S5B/P rats are genetically resistant to obesity when fed a high-fat diet. We hypothesized that the differential sensitivity of these two rat strains to natural rewards may also be reflected in sensitivity to drugs of abuse. Therefore, we tested whether OM and S5B/P rats showed a differential preference to cocaine using conditioned place preference (CPP). To also evaluate whether there is specific involvement of the D2R in this differential conditioning sensitivity, we then tested whether the D2R agonist bromocriptine (BC) would differentially affect the effects of cocaine in the two strains.
  
  
  METHODS
  OM and S5B/P rats were conditioned with cocaine (5 or 10mg/kg) in one chamber and saline in another for 8days. Rats were then tested for cocaine preference. The effects of BC (0.5, 1, 5, 10, 20mg/kg) on cocaine preference were then assessed in subsequent test sessions.
  
  
  RESULTS
  OM rats did not show a significant preference for the cocaine-paired chamber on test day. Only the S5B/P rats showed cocaine CPP. Later treatment with only the highest dose of BC resulted in reduced cocaine CPP in S5B/P rats when treated with 5mg/kg cocaine and in OM rats treated with 10mg/kg cocaine.
  
  
  CONCLUSIONS
  Our results indicated that obesity-resistant S5B rats showed greater cocaine CPP than the obesity-prone OM rats. These findings do not support a theory of common vulnerability for reinforcer preferences (food and cocaine). However, they show that BC reduced cocaine conditioning effects supporting at least a partial regulatory role of D2R in conditioned responses to drugs.
authors.affiliation: Laboratory of Neuroimaging, NIAAA, NIH, Department of Health and Human Services, Bethesda, MD, United States. thanos@bnl.gov
authors.forename: Panayotis K
authors.initials: PK
authors.lastname: Thanos
authors.forename: Ronald
authors.initials: R
authors.lastname: Kim
authors.forename: Jacob
authors.initials: J
authors.lastname: Cho
authors.forename: Michael
authors.initials: M
authors.lastname: Michaelides
authors.forename: Brenda J
authors.initials: BJ
authors.lastname: Anderson
authors.forename: Stefany D
authors.initials: SD
authors.lastname: Primeaux
authors.forename: George A
authors.initials: GA
authors.lastname: Bray
authors.forename: Gene-Jack
authors.initials: GJ
authors.lastname: Wang
authors.forename: John K
authors.initials: JK
authors.lastname: Robinson
authors.forename: Nora D
authors.initials: ND
authors.lastname: Volkow
mesh_terms: D000704:Analysis of Variance; D000818:Animals; D001245:Association Learning / Q000187:drug effects* / Q000502:physiology; D001971:Bromocriptine / Q000494:pharmacology; D003042:Cocaine / Q000494:pharmacology*; D003213:Conditioning, Psychological / Q000187:drug effects* / Q000502:physiology; D018491:Dopamine Agonists / Q000494:pharmacology; D018765:Dopamine Uptake Inhibitors / Q000494:pharmacology; D008297:Male; D009765:Obesity / Q000235:genetics*; D051381:Rats; D017448:Receptors, Dopamine D2 / Q000378:metabolism*
chemical_list: D018491:Dopamine Agonists; D018765:Dopamine Uptake Inhibitors; D017448:Receptors, Dopamine D2; D001971:Bromocriptine; D003042:Cocaine
references.citation: Philos Trans R Soc Lond B Biol Sci. 2008 Oct 12;363(1507):3191-200
references.pmid: 18640912
references.citation: Behav Neurosci. 2009 Feb;123(1):165-71
references.pmid: 19170441
references.citation: Lancet. 2001 Feb 3;357(9253):354-7
references.pmid: 11210998
references.citation: Physiol Behav. 2007 Aug 15;91(5):459-72
references.pmid: 17081571
references.citation: Neuroendocrinology. 2009;89(2):152-62
references.pmid: 18984941
references.citation: Brain Res. 1992 Sep 4;589(2):338-40
references.pmid: 1356596
references.citation: Pharmacol Biochem Behav. 1991 Jul;39(3):799-802
references.pmid: 1838414
references.citation: Synapse. 1993 Jun;14(2):169-77
references.pmid: 8101394
references.citation: Proc Natl Acad Sci U S A. 1998 Jun 23;95(13):7699-704
references.pmid: 9636213
references.citation: Behav Brain Res. 2006 Dec 15;175(2):415-9
references.pmid: 17000016
references.citation: J Neurosci. 2002 Nov 1;22(21):9595-603
references.pmid: 12417684
references.citation: Pharmacol Biochem Behav. 2007 Nov;88(1):89-93
references.pmid: 17764729
references.citation: Obes Res. 2002 Nov;10(11):1188-96
references.pmid: 12429884
references.citation: Life Sci. 1989;45(23):2247-54
references.pmid: 2601578
references.citation: Nat Neurosci. 2005 May;8(5):555-60
references.pmid: 15856062
references.citation: Synapse. 2008 Jan;62(1):50-61
references.pmid: 17960763
references.citation: J Hepatol. 2006 Sep;45(3):439-44
references.pmid: 16780999
references.citation: J Addict Dis. 2004;23(3):39-53
references.pmid: 15256343
references.citation: Neuroimage. 2008 Mar 1;40(1):275-9
references.pmid: 18096411
references.citation: Alcohol. 1997 Nov-Dec;14(6):603-9
references.pmid: 9401677
references.citation: Am J Public Health. 2004 Sep;94(9):1486-9
references.pmid: 15333299
references.citation: Science. 2008 Oct 17;322(5900):449-52
references.pmid: 18927395
references.citation: Synapse. 1998 Oct;30(2):181-93
references.pmid: 9723788
references.citation: Psychopharmacology (Berl). 1996 Aug;126(4):311-22
references.pmid: 8878347
references.citation: PLoS One. 2007 Aug 01;2(8):e698
references.pmid: 17668074
references.citation: Synapse. 2008 Jul;62(7):481-6
references.pmid: 18418874
references.citation: Behav Neurosci. 2008 Dec;122(6):1257-63
references.pmid: 19045945
references.citation: Nature. 1997 Apr 24;386(6627):827-30
references.pmid: 9126740
references.citation: Psychopharmacology (Berl). 1991;105(2):151-6
references.pmid: 1839063
references.citation: Am J Addict. 1997 Winter;6(1):54-64
references.pmid: 9097872
references.citation: Drug Alcohol Depend. 2006 Feb 1;81(2):189-95
references.pmid: 16051446
references.citation: Pharmacol Ther. 2005 Oct;108(1):3-17
references.pmid: 16098597
references.citation: Alcohol Clin Exp Res. 2004 May;28(5):720-8
references.pmid: 15166646
references.citation: Neuropsychopharmacology. 1990 Apr;3(2):101-8
references.pmid: 2317262
references.citation: J Nutr. 1970 Sep;100(9):1041-8
references.pmid: 5456549
references.citation: Am J Physiol. 1996 Mar;270(3 Pt 2):R489-95
references.pmid: 8780212
references.citation: Neurosci Lett. 1987 Aug 31;79(3):315-20
references.pmid: 2958724